Aim The aim of this study was to evaluate whether adjuvant chemotherapy will affect recurrence rate or diseasefree and overall survival in patients with rectal adenocarcinoma who were staged with MRI node-positive disease (mrN+) preoperatively. These patients underwent neoadjuvant chemoradiotherapy with curative rectal cancer surgery and their pathological staging was negative for nodal disease (ypN0). There is no consensus on the role of adjuvant chemotherapy in such patients.
Introduction
Colorectal cancer is the third most common in the world, and rectal cancer accounts for 30-40% of these malignancies [1, 2] . In rectal cancer with nodal disease, neoadjuvant chemoradiotherapy followed by total mesorectal excision (TME), aiming to harvest 12 or more lymph nodes in the specimen, is the recommended standard of treatment [3] .
The use of adjuvant chemotherapy especially in the context of previous neoadjuvant treatment, is controversial [4, 5] . Fluoropyrimidine-based adjuvant chemotherapy has been widely used, and the addition of oxaliplatin was based on data from patients with colon cancer [2, 6] . For many years colon and rectal cancers were considered as a single entity [6] [7] [8] and much of the evidence looking at the use of adjuvant therapy in rectal cancer is taken from studies looking at colon and rectal cancer together. This was based on the logic that they are histologically similar and are in organ continuity [6] [7] [8] [9] . However, they should be considered separately as the rectum is deep in the pelvis and is covered by surrounding tissue on all sides. It has different lymphatic drainage, it responds to chemotherapy in a different way and historically has a higher rate of local recurrence [6, 7, 9] .
Studies in locally advanced rectal cancer have shown a benefit to neoadjuvant chemoradiotherapy by significantly reducing the recurrence rates [10] [11] [12] , although this has not been conclusively followed by an improvement in overall survival [6, [10] [11] [12] . In the event of a complete pathological response to neoadjuvant chemoradiotherapy there is improved local and distal control with a benefit for overall and disease-free survival [13] . Conversely patients with tumours that are refractory to neoadjuvant therapy, where the T stage is not reduced, have a much poorer outcome [14] . Lymph node nonresponse after neoadjuvant chemotherapy is associated with increased distant metastasis and is an independent risk factor for decreased 5-year diseasefree survival [15, 16] .
In the event that a patient is diagnosed preoperatively as being lymph node positive (mrT(any)N+ M0) and after neoadjuvant therapy becomes lymph node negative (ypT(any)N0 M0) there is a paucity of evidence as to the benefits of treatment with adjuvant therapy [4, 7, 17] . As a result, a clear consensus is lacking; there are no guidelines, leading to a variation in practice [4, 7, 17] . Previous studies have shown that adjuvant therapy is of little benefit in ypT0-2 N0 patients, but its benefits in ypT3-4 N0 are less understood and are controversial [2, 5] . Practice includes blanket policies of 'yes to all' or 'no to all', or an individualized case by case plan based on high-risk features, such as the presence of extramural vascular invasion (EMVI) or high T stage [8, [17] [18] [19] . If adjuvant chemotherapy is not given when there was preoperative evidence of nodal metastasis (mrN+) an early recurrence would raise the question of under-treatment. However, giving chemotherapy with no clear benefit risks overtreating patients and subjecting them to the side effects of chemotherapy [7, 9] . This is a retrospective look at a selected group of patients with the aim of investigating the merits, in terms of overall survival and disease-free survival, of adjuvant chemotherapy in the event that mrT(any)N+ M0 becomes ypT(any)N0 M0 after neoadjuvant therapy.
Methods
A retrospective analysis of patients with rectal cancer who received neoadjuvant treatment in two tertiary referral centres (Saint-Andre Hospital, University of Bordeaux, France and The Royal Marsden Hospital, London, UK) between January 2008 and December 2012 was performed. Patient identification number, sex, age, body mass index (BMI) and American Society of Anesthesiologists (ASA) grade and preoperative and pathological staging were obtained. We identified patients with rectal cancer, regardless of T stage, who were initially lymph node positive without metastasis, (mrT(any)N+ M0) on preoperative imaging. A subgroup of patients who had a full lymph node response and so had no cancer-positive lymph nodes (ypT(any)N0 M0) in the postoperative pathological specimen were selected. These patients were divided into two groups on the basis of whether or not they received adjuvant chemotherapy.
The primary end-point is the reduction in the recurrence rate of of local and distant cancer postoperatively. The secondary end-points are the effects on overall and disease-free survival.
All patients were evaluated initially with a full history, physical examination and blood tests, followed by an endoscopy and biopsy. Patients were imaged with computed tomography (CT) of the chest, abdomen and pelvis followed by a pelvic magnetic resonance imaging (MRI) scan. If there was any suggestion of metastasis then a positron emission tomography (PET) scan was used to assess this further. All patients were discussed and the treatment planned in a multidisciplinary team meeting.
Neoadjuvant treatment was given according to European guidelines. The patients received radiation of 50 Gy in 25 fractions over 5 weeks with concomitant chemotherapy with 5-fluorouracil (5-FU). During the second half of the study period patients received induction chemotherapy in addition to long-course chemoradiotherapy based on double or triple cytotoxic therapy of 5-FU and oxaliplatin or 5-FU, oxaliplatin and irinotecan, respectively.
Surgery was performed with curative intent in all patients and was undertaken 6-8 weeks after neoadjuvant therapy in one of the two tertiary colorectal centres cited above by a consultant lead team experienced in advanced and complex rectal cancer surgery.
The decision to administer adjuvant chemotherapy was made locally on a case by case basis in the multidisciplinary team meeting and there was no randomization. Factors affecting the decision included the overall health of the patient in conjunction with risk factors for recurrence that was in keeping with previous local practice. If deemed necessary then 5-FU and oxaliplatin were administered.
Outcome data for the two groups were obtained retrospectively from the physical and computerized records. Type of operation, anastomosis technique, height of anastomosis, resection status, pathological TNM staging, the number of lymph nodes in the specimen and the number of positive lymph nodes, the time to local and distant recurrence and postoperative survival were all recorded.
Statistical analysis
The two groups were propensity matched at a ratio of two to one based on patient age, pathological tumour stage, resection margin, EMVI and tumour grade.
Log-rank (Mantel-Cox) was used to compare the two groups in terms of time to distant recurrence, overall and disease-free survival. For tumour downstaging and complete pathological tumour response Pearson's chi-square test was used to compare proportions between the groups, except if one of the cells had a value of less then 5 in which case Fisher's exact test was used. The threshold for statistical significance was 0.05 throughout.
All data were collated using Microsoft Excel (2007; Redmond, Washington, USA) and all statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) (Armonk, New York, USA).
Results
A total of 163 patients were enrolled in the study: 124 had no adjuvant chemotherapy and 39 had adjuvant therapy. After propensity score matching, at a ratio of 2 to 1, 80 patients were included in the analysis: 52 patients did not receive adjuvant chemotherapy and 28 patients received adjuvant chemotherapy.
The patients who were included were operated on between February 2008 and December 2012 at SaintAndre Hospital, University of Bordeaux, France and The Royal Marsden Hospital, London, UK. In both groups there were 29 women and 51 men, the mean (range) age was 59.7 (36-84) years and the mean BMI was 26.0 (18.7-38) kg/m. Demographics are displayed according to the groups in Table 1 . Preoperative and postoperative tumour staging data are shown in Table 2 .
All 80 patients were selected as being specifically lymph node positive on preoperative MRI scans (N1 70/80 and N2 10/80) and pathologically having no cancer remaining in the lymph nodes postoperatively.
The median number of lymph nodes harvested was 13 (range 2-26) in the adjuvant group and 17 (range 4-34) in the no-adjuvant group. In the adjuvant group 21/28 (75%) were anterior resections, 5/28 (18%) were abdominoperineal excisions of the rectum and 2/28 (7%) were pelvic exenterations. In the no-adjuvant group 46/52 (88%) were anterior resections, 3/52 (6%) were abdominoperineal excisions of the rectum, 2/52 (4%) were total pelvic exenterations and 1/52 (2%) was a Hartmann's operation. All patients in both groups underwent a complete (R0) resection.
The tumour response to neoadjuvant chemotherapy between the two groups showed that 16/28 (57%) and 36/52 (69%) patients had a reduced T stage (P = 0.28) and 4/28 (14%) and 6/52 (12%) had a pathological complete response (P = 0.73) in the adjuvant vs the noadjuvant groups, respectively ( Table 3 ). The mean length of follow-up of the entire cohort was 3.28 years, with a range of 0.02-7.32 years.
Recurrence outcomes
In the group receiving adjuvant chemotherapy (n = 28) there were six recurrences (four distant recurrence and two with both local and distant recurrence) and one death (after 2 years and 11 months with both distant and local recurrence). In the group that did not receive adjuvant chemotherapy (n = 52) there were eight recurrences, which were all distant, with an average time to recurrence of 3.32 (0.10-6.88) years. There were five deaths: two with distant recurrence, both after 2.2 years and three with no recurrence after 0.1, 2.9 and 6.3 years. There was no statistically significant difference in distant recurrence rates (P = 0.14) between the groups that did and did not receive adjuvant chemotherapy. There was no local recurrence in the group that did not receive adjuvant chemotherapy.
Survival outcomes
Comparison between the adjuvant therapy and no adjuvant therapy groups showed no statistically significant difference in overall survival (P = 0.42) or disease-free survival (P = 0.14). The mean overall survival of the two groups, adjuvant vs no adjuvant therapy, was 2.67 (0.02-7.32) years vs 3.60 (0.10-6.88) years and mean disease free survival was 2.27 (0.02-7.3) years vs 3.32 (0.10-6.88) years, respectively (Table 4 , Figs. 1 and 2 ).
Discussion
This analysis showed better overall survival, disease-free survival and time to distant recurrence in the group having no adjuvant treatment; however, the differences were not statistically significant. The limitations of this work are that it is retrospective in nature, with no randomization and unequal groups. There were significantly more ASA grade I patients in the group that did not receive adjuvant therapy and the specific types of rectal cancer operation in each group were not precisely matched, which may have an effect on survival. Despite looking at two tertiary centres, both of which treat large numbers of patients with rectal cancer, few patients were selected in terms of lymph node status, which leaves small sample sizes that may limit the statistical analysis. Preoperative radiological and postoperative pathological stagings were undertaken by a consultant working in a specialized colorectal centre, but there was no secondary analysis checking for agreement on staging. Both groups showed downstaging of T stage with some complete pathological responses noted, although there was no significant difference between the groups.
In locally advanced rectal cancer, neoadjuvant chemoradiotherapy with a total mesorectal excision is the standard of treatment, as it can downstage the disease [6, [10] [11] [12] [14] [15] [16] . Furthermore, reduction in the lymph node staging is seen in 30-60% of lymph node-positive patients [16, [20] [21] [22] [23] . This overall downstaging of tumour and lymph nodes leads to an improvement in local and distant control and in disease-free and overall survival [7, [13] [14] [15] [16] . It is shown that failure to downstage in terms of T stage, N stage or both is a very poor prognostic sign [16, 24] . A study by Kim et al. [24] noted a 5-year disease-free survival of 84%, 68% and 27% for ypN0, ypN1 and ypN2 disease, respectively, which raises the question as to whether or not patients who remain ypN+ should be given adjuvant chemotherapy in an attempt to improve their outcome [16, 24] . In 2007 Bujko et al. [15] stated that lymph node positivity leads to such a poor outcome that these patients should be considered for adjuvant chemotherapy [15] , but a systematic review in 2010 noted that none of the trial data on this topic supported a survival benefit when given for rectal cancer [9] . There have been four clinical randomized trials [25] [26] [27] [28] looking into the use of adjuvant chemotherapy in advanced rectal cancer; none have shown a benefit on overall or disease-free survival. However, some of the data are lacking, with poor accrual and high dropout rates, and they do not all use the same cytotoxic agents or regimes [25] [26] [27] [28] . Kiran et al. [29] conducted a similar study to ours in 2012 and found no benefit from giving adjuvant therapy to patients who had a curative resection and were lymph node negative after neoadjuvant therapy. A randomized controlled trial by the European Organisation for Research and Treatment of Cancer (EORTC) showed no benefit from giving adjuvant therapy after neoadjuvant chemoradiotherapy, even in the presence of node-positive disease [9, 10, 18, 27] .
In America the Mayo/North Central Cancer Treatment Group have recommended adjuvant treatment with 5-FU with T3 N1-2 disease since 1990 [7] . In 2009 the European Society for Medical Oncology recommendations stated that Stage III and 'high-risk' Stage II patients should be given adjuvant chemotherapy, and acknowledged that the evidence for it is 'less' and that it is based on data from colon cancer [8] . In 2015 the National Comprehensive Cancer Network guidelines recommended postoperative chemotherapy for all patients undergoing preoperative chemoradiation, regardless of the surgical pathology results [19] .
The lack of direct evidence on this topic to support the current guidelines has led to a varied practice internationally and this makes studying this topic difficult. However, the question is relevant and of interest, as underand over-treatment present difficulties [4, 7, 8, 17] .
In conclusion, the question posed in this paper is clinically relevant because the appropriate targeting of cytotoxic therapies is vital. The literature and guidelines are juxtaposed and this has created variation in practice. The data we used have some flaws that have been discussed, but they are in agreement with the published literature in not showing any significant benefits for overall or disease-free survival to giving adjuvant chemotherapy in this setting. A sufficiently powered and randomized controlled trial is required to be definitive on the benefits of adjuvant chemotherapy in this scenario.
